tag janssen 
pharmaphorum
NOVEMBER 24, 2022
One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems. and 17.6%, respectively, according to J&J’s pharma unit Janssen. and 14.1%, respectively.
pharmaphorum
JULY 25, 2022
The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab, along with talquetamab which binds to CD3 and GPRC5D.
pharmaphorum
NOVEMBER 28, 2022
Substra is the software that powered the MELLODDY platform, a collaboration in which Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data — but not with each other directly, nor with Owkin.
Expert insights. Personalized for you.
52 
Let's personalize your content